Skip to content
Business Segments · Depreciation

Biotechnology — Depreciation

Danaher Biotechnology — Depreciation increased by 2.6% to $40M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 17.6%, from $34M to $40M. Over 2 years (FY 2023 to FY 2025), Biotechnology — Depreciation shows relatively stable performance with a -4.1% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.

Analysis

StatementSegment
CategoryEfficiency
SignalLower is better
VolatilityStable
First reportedQ1 2023
Last reportedQ1 2026Apr 21, 2026
Rolls up toD&A

How to read this metric

High levels relative to revenue may indicate an aging asset base or high capital intensity.

Detailed definition

The systematic allocation of the cost of tangible fixed assets over their useful lives within the biotechnology segment....

Peer comparison

Commonly reported as part of segment-level operating expenses in industrial and life science companies.

Metric ID: dhr_segment_biotechnology_depreciation

Historical Data

13 periods
 Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Value$40.5M$40.5M$40.5M$40.5M$42M$35M$36M$38M$34M$38M$38M$39M$40M
QoQ Change+0.0%+0.0%+0.0%+3.7%-16.7%+2.9%+5.6%-10.5%+11.8%+0.0%+2.6%+2.6%
YoY Change+3.7%-13.6%-11.1%-6.2%-19.0%+8.6%+5.6%+2.6%+17.6%
Range$34M$42M
CAGR-0.4%
Avg YoY Growth-1.3%
Median YoY Growth+2.6%
Current Streak4 quarters growth

Frequently Asked Questions

What is Danaher's biotechnology — depreciation?
Danaher (DHR) reported biotechnology — depreciation of $40M in Q1 2026.
How has Danaher's biotechnology — depreciation changed year-over-year?
Danaher's biotechnology — depreciation increased by 17.6% year-over-year, from $34M to $40M.
What is the long-term trend for Danaher's biotechnology — depreciation?
Over 2 years (2023 to 2025), Danaher's biotechnology — depreciation has grown at a -4.1% compound annual growth rate (CAGR), from $162M to $149M.
What does biotechnology — depreciation mean?
The non-cash expense representing the aging of physical assets in the biotechnology segment.